Table 1.
Baseline characteristics of the study group subjects 1,2,3.
| Zinc supplement patients (n=40) | Control group patients (n=25) | Healthy subjects (n=38) | |
|---|---|---|---|
| Age (yrs) | 59 ± 10 | 61 ± 8 | 60 ± 5 |
| Gender (M/F) | 22/18 | 14/11 | 20/18 |
| Dialysis duration (months) | 62 ± 12 | 64 ± 10 | - |
| Body mass index, BMI (kg/m2) | |||
| Beginning of study | 23 ± 2 | 22 ± 3 | 24 ± 2 |
| End of study | 24 ± 3b | 21 ± 3a | - |
| BUN (mg/dl) | 69 (61-80)b | 67 (56-87)b | 18 (9-26)a |
| Creatinine (mg/dl) | 10.3 ± 3.0b | 9.3 ± 2.0b | 1.8 ± 0.6a |
| Albumin (mg/dl) | 3.2 (2.9-3.7)a | 3.4 (2.9-3.6)a | 4.7 (4.0-5.4)b |
| Hemoglobin (gm%) | 9.6 ± 0.8a | 9.7 ± 0.8a | 16.8 ± 1.1b |
| nPNA (g/kg/day) | 0.9 ± 0.3 | 1.0 ± 0.3 | - |
| eGFR (mL/min/1.73 m2) | 4.8 (4.0-7.0) | 5.3 (4.8-6.5) | - |
| Kt/V (/week) | 1.3 ± 0.1 | 1.4 ± 0.1 | - |
| Diabetes mellitus (%) | 30 | 32 | - |
| Hypertension (%) | 10 | 8 | - |
| Dyslipidemia (%) | 13 | 12 | - |
| Ischemic heart disease (%) | 30 | 32 | |
| Other drugs use | |||
| Insulin (%) | 10 | 8 | - |
| Sulfonylurea (%) | 20 | 24 | - |
| Statin (%) | 0 | 0 | - |
| Ca+2 channel antagonists (%) | 25 | 23 | - |
| β-blocker (%) | 15 | 13 | - |
| Triglyceride (mg/dL) | 136 ± 106 | 129 ± 96 | 130 ± 45 |
| Fasting glucose (mg/dL) | 109 ± 9 | 103 ± 8 | 94 ± 9 |
| Smoking (%) | 5 | 4 | 5 |
| Alcohol consumption (%) | 0 | 0 | 0 |
1 Values are mean ± SD or medians (inter-quartile range). 2 Values in the same row with different superscripts are significantly different (p < 0.05). 3 BUN = blood urea nitrogen; nPNA = protein equivalent of total nitrogen appearance normalized to body weight; eGFR = estimated glomerular filtration rate; Kt/V = clearance of urea normalized to total body water.